A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
Public ClinicalTrials.gov record NCT03697109. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance (DM/IGT) and/or uncontrolled hypertension (HTN).
Study identification
- NCT ID
- NCT03697109
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 152 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2018 (Actual)
- Primary completion
- Apr 8, 2024 (Actual)
- Completion
- Apr 15, 2024 (Actual)
- Last update posted
- Jul 16, 2025
2018 – 2024
United States locations
- U.S. sites
- 32
- U.S. states
- 22
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 21 | Phoenix | Arizona | 85013 | — |
| Site 36 | Los Angeles | California | 90095 | — |
| Site 68 | Torrance | California | 90502 | — |
| Site 10 | Miami | Florida | 33136 | — |
| Site 14 | Atlanta | Georgia | 30318 | — |
| Site 41 | Chicago | Illinois | 60611 | — |
| Site 7 | Indianapolis | Indiana | 46202 | — |
| Site 2 | Metairie | Louisiana | 70006 | — |
| Site 45 | Baltimore | Maryland | 21205 | — |
| Site 46 | Boston | Massachusetts | 02115 | — |
| Site 20 | Ann Arbor | Michigan | 48109 | — |
| Site 4 | Jackson | Mississippi | 39202 | — |
| Site 13 | St Louis | Missouri | 63110 | — |
| Site 53 | Omaha | Nebraska | 68198 | — |
| Site 72 | Reno | Nevada | 89511 | — |
| Site 8 | Albany | New York | 12203 | — |
| Site 6 | Jamaica | New York | 11432 | — |
| Site 57 | New York | New York | 10021 | — |
| Site 35 | New York | New York | 10029 | — |
| Site 39 | New York | New York | 10065 | — |
| Site 1 | Wilmington | North Carolina | 28401 | — |
| Site 17 | Columbus | Ohio | 43210 | — |
| Site 11 | Oklahoma City | Oklahoma | 73104 | — |
| Site 62 | Philadelphia | Pennsylvania | 19107 | — |
| Site 19 | Pittsburgh | Pennsylvania | 15212 | — |
| Site 71 | Pittsburgh | Pennsylvania | 15213 | — |
| Site 5 | Summerville | South Carolina | 29485 | — |
| Site 51 | Dallas | Texas | 75390 | — |
| Site 3 | El Paso | Texas | 79935 | — |
| Site 65 | Houston | Texas | 77079 | — |
| Site 56 | Shavano Park | Texas | 78231 | — |
| Site 31 | Everett | Washington | 98201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03697109, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 16, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03697109 live on ClinicalTrials.gov.